Stock Analysis, Dividends, Split History

LM / Legg Mason, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price30.71
Volume1,008,600.00
Market Cap ($M)2,625.91
Enterprise Value ($M)2,625.91
Book Value / Sharen/a
Price / Bookn/a
NCAV ($M)0.00
NCAV / Share0.00
Price / NCAVn/a
Share Statistics
Common Shares Outstanding 95,860,683
Common Stock Shares Outstanding 95,727,000
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets0.00
Liabilities0.00
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Revenues2,886,902,000.00
Cash Flow Statement (mra) ($M)
Identifiers and Descriptors
CUSIP524901105
Central Index Key (CIK)704051
Related CUSIPS
524901955 524901905 524901501

Split History

Stock splits are used by Legg Mason, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Blackrock: Crown Jewel + Hidden Gem = Opportunity

4h seekingalpha
A decade ago, the US was enduring a brutal financial crisis. Many still have memories are bankruptcies, massive losses, home foreclosures, reckless insurers, CDS (credit default swaps) bets and billion-dollar bank bailouts. With the 10-yr anniversary of Lehman Brothers bankruptcy just occurring, most investors remember the losses and pain of the financial crisis. While we learned much from enduring this time-period, as well as the dot-com bust, we thought we would spend some time reviewing a winner from this environment. (6-0)

Oracle Corporation (ORCL) CEO Safra Catz and Mark Hurd on Q1 2019 Results - Earnings Call Transcript

21h seekingalpha
Thank you, Victoria. Good afternoon, everyone, and welcome to Oracle’s first quarter fiscal year 2019 earnings conference call. A copy of the press release and financial tables, which includes the GAAP to non-GAAP reconciliation and other financial information, can be viewed and downloaded from our Investor Relations website. (22-0)

Legg Mason AUM Ascends in August, Liquidity Inflows Recorded

2018-09-17 zacks
Legg Mason Inc. (LM - Free Report) reported a slight rise in assets under management (AUM) as of Aug 31, 2018, from the prior month. Preliminary month-end AUM came in at $751.8 billion, up from the July 2018 figure of $749.2 billion. August AUM displayed $0.7-billion fixed income outflows, equity net outflows of $0.6 billion and alternative net outflows of $0.1 billion, fully offset by $2.9 billion of liquidity inflows. (1-0)

Is ClearBridge Small Cap Growth A (SASMX) a Strong Mutual Fund Pick Right Now?

2018-09-14 zacks
If you have been looking for Small Cap Growth funds, a place to start could be ClearBridge Small Cap Growth A (SASMX - Free Report) . SASMX possesses a Zacks Mutual Fund Rank of 1 (Strong Buy), which is based on nine forecasting factors like size, cost, and past performance. (6-0)

Franklin's (BEN) August AUM Descends 1.5% on Net Outflows

2018-09-12 zacks
Franklin Resources (BEN - Free Report) has announced preliminary assets under management (AUM) by its subsidiaries of $722.4 billion for August 2018. Results display 1.5% fall from $733.7 billion recorded as of Jul 31, 2018. Net market losses and net outflows were undermining factors. Further, the figure dipped 3.3% from the previous year. Month-end total equity assets came in at $312.9 billion, down around 1. (1-0)

CUSIP: 524901105